Barts Endocarditis Research Registry
Launched by QUEEN MARY UNIVERSITY OF LONDON · May 23, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Barts Endocarditis Research Registry is a study aimed at understanding a serious heart infection called Infective Endocarditis (IE). This research will look at how common this condition is, the different imaging methods used to diagnose it, and how current treatment guidelines are being followed. By gathering information about patients' experiences, treatments, and outcomes, the registry will help improve how we diagnose and manage this infection in the future. It will also lay the groundwork for future studies that may lead to better treatment options.
To participate in this study, individuals must be at least 16 years old and have been diagnosed with endocarditis, whether they are currently in the hospital or seeing a doctor for follow-up care. Participants will need to provide consent to be part of the research. This registry is currently active, but it is not recruiting new participants at this time. Overall, this research is important as it aims to improve our understanding and treatment of endocarditis, benefiting patients in the long run.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Patients aged 16 and over (Patients under 16 years of age are not admitted to Barts Heart Centre)
- • Patients admitted to Barts Heart Centre with confirmed Endocarditis (see above)
- • Patients attending outpatients with confirmed/suspected Endocarditis
- • Patients with possible IE who complete treatment for endocarditis
- • Patients with cardiac device related Endocarditis
- • Patients with the ability to provide informed consent
- Exclusion Criteria:
- • • Patients with pacemaker pocket infection with no evidence of pacemaker lead or valve infection
- • Patients who refuse consent to be included in the research database
- • Patients with "rejected" endocarditis
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Simon Woldman, MSc
Principal Investigator
St Bartholomews Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported